Reuters: Health
Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.
Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study
Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study
Reuters: Health
Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.
Reuters: Health
Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment